← 產業報告目錄

Digital Biomarkers Market by Type (Physiological, Vocal, Idiosyncratic), Therapy [Cardio, Onco (Lung, Breast Cancer), Mental Health, Neuro], Application [Clinical Research (Phase IV)], End User (Pharma & Biotech Companies, CROs) – Global Forecast to 2031

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2026-04-06頁數 402報告編號 BT10252

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global digital biomarkers market is projected to reach USD 17.73 billion by 2031, growing from USD 7.41 billion in 2026 at a CAGR of 19.1%. The digital biomarkers market is being driven by the rapid evolution of data-driven clinical trials and the growing trend of integrating digital health technology into clinical trials. Pharmaceutical and biotech companies are increasingly using digital biomarkers in various stages of clinical trials to enable continuous and objective patient monitoring, thus improving data quality and endpoint accuracy. This is a part of a larger trend towards more efficient and patient-centric clinical trials, in which data from real-world sources plays a crucial role in determining the effectiveness of a drug. At the same time, there is a growing trend toward more decentralized clinical trials, in which data is collected more frequently by using remote data collection technology such as wearable devices and sensor technology. This is a part of a larger trend towards more digital biomarker software technology in clinical trials. “By type, the physiological biomarkers segment is expected to account for the largest market share of the digital biomarkers market during the forecast period.” By type, the physiological biomarkers segment is expected to hold the largest share of the digital biomarkers market during the forecast period. This is mainly due to the widespread use of continuous physiological measures like heart rate, ECG, respiratory rate, and activity levels in various clinical research and patient care settings. Physiological biomarkers are scalable and are well validated, making them more suitable for remote patient monitoring and chronic disease management. In addition, the growing trend of using software platforms and AI-based tools associated with wearable devices is further propelling their adoption, particularly in cardiovascular and metabolic conditions where continuous monitoring is critical in making clinical decisions. This is also evident from published research that states that physiological data streams like heart rate and activity levels are some of the most commonly used digital endpoints in clinical trials, mainly due to their objectivity and ability to provide high-frequency and real-world data. In addition, the move towards decentralized trials and RWE generation is also further solidifying their position in the field of digital biomarkers, as they allow for patient monitoring outside traditional clinical environments. In June 2025, AliveCor, Inc. (US) partnered with the British Heart Foundation (UK), donating proceeds from its KardiaMobile 6L device to support cardiovascular research and promote the adoption of digital heart rhythm monitoring technologies. These examples further hint at the growing role of physiological digital biomarkers in advancing cardiac care and research. “By end user, the hospitals & specialty clinics segment is expected to achieve the fastest growth during the forecast period.” By end user, the hospitals & specialty clinics segment is expected to witness the highest growth in the digital biomarkers market over the forecast period. The growth in this segment can be attributed to the rising adoption of digital biomarkers in hospitals and specialty clinics for real-time patient monitoring. Digital biomarkers are being increasingly integrated into the workflows of hospitals and specialty clinics for data-driven decision-making. Hospitals and specialty clinics are adopting wearable-enabled platforms and artificial intelligence-based analytics solutions for continuously monitoring physiological, cognitive, and behavioral changes in patients. Digital biomarkers help hospitals and specialty clinics in continuously monitoring patient data in real-time, thus helping in the early detection of changes in patient health. Moreover, the rising trend of value-based care is fueling the adoption of remote monitoring solutions in hospitals and specialty clinics. The rising prevalence of chronic diseases such as cardiovascular diseases, neurological disorders, and diabetes is also contributing to the growth of the digital biomarkers market in hospitals and specialty clinics. The rising trend of health information technology, which allows for seamless integration of digital biomarker solutions into electronic health records, is also fueling the growth of the digital biomarkers market in hospitals and specialty clinics. “Asia Pacific to witness the highest growth rate during the forecast period.” The digital biomarkers market in Asia Pacific is growing rapidly, with the region witnessing high growth in the expansion of clinical research activities. The region is witnessing the incorporation of digital technologies into the healthcare infrastructure. Countries such as India, South Korea, Japan, and Australia are gaining importance as hubs for clinical research activities. Due to the improvement in the regulatory environment and the cost advantage, the pharmaceutical and biotech industries are increasingly using the Asia Pacific as a hub for conducting clinical research activities. As the pharmaceutical and biotech industries increasingly rely on digital technologies to conduct clinical research activities, the digital biomarkers market is growing rapidly. Asia Pacific is witnessing the incorporation of digital technologies into the healthcare infrastructure. The region is witnessing the expansion of clinical research activities. In November 2025, Lunit Inc., a South Korean-based company, announced its collaboration with Labcorp to conduct research using digital pathology technology powered by artificial intelligence and expand access to imaging-based biomarkers for clinical and translational oncology research globally. Such developments indicate the potential of the region as a lucrative market for digital biomarkers. The breakdown of primary participants is as follows: • By Company Type – Tier 1 Companies: 60%, Tier 2 Companies: 30%, and Tier 3 Companies: 10% • By Designation – C-level Executives: 30%, Director-level Personnel: 50%, and Other Designations: 20% • By Region – North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the world: 10% IXICO PLC (UK), Ametris, LLC (US), and Empatica, Inc. (US) are some of the key players in the digital biomarkers market. The study includes an in-depth competitive analysis of these key players, their company profiles, recent developments, and key market strategies. Research Coverage: This research report categorizes the digital biomarkers market by type (physiological biomarkers, idiosyncratic biomarkers, cognitive biomarkers, vocal biomarkers, and other biomarkers), therapeutic area {cardiovascular [atherosclerotic cardiovascular disease (ASCVD)/secondary prevention, heart failure (HFrEF and HFpEF), hypertension, atrial fibrillation (AF)/stroke prevention, pulmonary hypertension, and structural heart disease/interventional cardiology], oncology (solid tumors, hematologic malignancies), diabetes, mental health & behavioral health, respiratory disorders, lifestyle & wellness improvement, neurology, musculoskeletal disorders/pain management, women’s health & reproductive health, and other diseases}, application, [clinical research applications (phase II, phase III, phase IV) and clinical care applications], end user [pharmaceutical and biotechnology companies, contract research organizations (CROs), hospitals and specialty clinics, and others (including research institutes, etc.)] and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the digital biomarkers market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions and services; contracts, partnerships, agreements, product & service launches, mergers & acquisitions; and recent developments associated with the digital biomarkers market. Competitive analysis of upcoming startups in the digital biomarkers market ecosystem is covered in this report. Reasons to Buy this Report: The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the digital biomarkers market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. The report provides insights into the following pointers: • Analysis of key drivers (Expansion of smartphones, wearables, and connected health ecosystems; expansion of decentralized and remote clinical trials; rising prevalence of chronic diseases requiring continuous monitoring; advancements in AI and digital health analytics) restraints (Data privacy and security concerns related to health data, limited digital literacy and technology access among patients) opportunities (Increasing use of digital biomarkers in drug development and clinical trial endpoints, growth of precision medicine and personalized healthcare, emerging applications in neurological and mental health monitoring), challenges (Lack of standardized validation frameworks for digital biomarkers, regulatory uncertainty around digital endpoints and biomarker validation) influencing the growth of the digital biomarkers market • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product & service launches in the digital biomarkers market • Market Development: Comprehensive information about lucrative markets across varied regions • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the digital biomarkers market • Competitive Assessment: In-depth assessment of market share, growth strategies, and service offerings of leading players, namely IXICO PLC (UK), Ametris, LLC (US), Empatica, Inc. (US), AliveCor, Inc. (US), CONNEQT Health (US), VivoSense (US), BioSensics (US), Lunit, Inc. (South Korea), among others, in the digital biomarkers market
目錄 Table of Contents
1 INTRODUCTION 35 1.1 STUDY OBJECTIVES 35 1.2 MARKET DEFINITION 35 1.3 MARKET SCOPE 36 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 36 1.3.2 INCLUSIONS & EXCLUSIONS 37 1.3.3 YEARS CONSIDERED 38 1.4 CURRENCY CONSIDERED 38 1.5 LIMITATIONS 39 1.6 STAKEHOLDERS 39 2 EXECUTIVE SUMMARY 41 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 41 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 43 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 44 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 45 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 46 3 PREMIUM INSIGHTS 47 3.1 DIGITAL BIOMARKERS MARKET OVERVIEW 47 3.2 DIGITAL BIOMARKERS MARKET, BY APPLICATION & REGION 48 3.3 DIGITAL BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT 48 4 MARKET OVERVIEW 49 4.1 INTRODUCTION 49 4.2 MARKET DYNAMICS 50 4.2.1 DRIVERS 50 4.2.1.1 Expansion of smartphones, wearables, and connected health ecosystems 50 4.2.1.2 Expansion of decentralized and remote clinical trials 51 4.2.1.3 Rising prevalence of chronic diseases that require continuous monitoring 52 4.2.1.4 Advancements in AI and digital health analytics 52 4.2.2 RESTRAINTS 53 4.2.2.1 Data privacy and cybersecurity concerns 53 4.2.2.2 Limited digital literacy and technology access among patients 53 4.2.3 OPPORTUNITIES 54 4.2.3.1 Increasing use in drug development and clinical trial endpoints 54 4.2.3.2 Growth of precision medicine and personalized healthcare 54 4.2.3.3 Emerging applications in neurological and mental health monitoring 55 4.2.4 CHALLENGES 55 4.2.4.1 Lack of standardized validation frameworks for digital biomarkers 55 4.2.4.2 Regulatory uncertainty around digital endpoints and biomarker validation 55 4.3 UNMET NEEDS AND WHITE SPACES 56 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 56 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 57 5 INDUSTRY TRENDS 58 5.1 PORTER’S FIVE FORCES ANALYSIS 58 5.1.1 BARGAINING POWER OF SUPPLIERS (MODERATE) 59 5.1.2 BARGAINING POWER OF BUYERS (HIGH) 59 5.1.3 THREAT OF SUBSTITUTES (MODERATE TO HIGH) 59 5.1.4 THREAT OF NEW ENTRANTS (MODERATE) 59 5.1.5 INTENSITY OF COMPETITIVE RIVALRY (HIGH) 60 5.2 MACROECONOMIC INDICATORS 60 5.2.1 INTRODUCTION 60 5.2.2 GDP TRENDS AND FORECAST 60 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 60 5.3 SUPPLY CHAIN ANALYSIS 61 5.4 ECOSYSTEM ANALYSIS 62 5.5 PRICING ANALYSIS 64 5.5.1 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY KEY PLAYER (2025) 64 5.5.2 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY REGION (2025) 65 5.6 KEY CONFERENCES AND EVENTS, 2026–2027 65 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 67 5.8 INVESTMENT AND FUNDING SCENARIO 67 5.9 CASE STUDY ANALYSIS 68 5.10 IMPACT OF 2025 US TARIFF ON DIGITAL BIOMARKERS MARKET 70 5.10.1 INTRODUCTION 70 5.10.2 KEY TARIFF RATES 71 5.10.3 PRICE IMPACT ANALYSIS 72 5.10.4 IMPACT ON COUNTRY/REGION 72 5.10.4.1 US 72 5.10.4.2 Europe 72 5.10.4.3 Asia Pacific 73 5.10.5 IMPACT ON END USERS 73 5.10.5.1 Pharmaceutical and biotechnology companies 73 5.10.5.2 Contract research organizations 73 5.10.5.3 Hospitals and specialty clinics 73 5.10.5.4 Others (research institutes, etc.) 74 6 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 75 6.1 INTRODUCTION 75 6.2 DECISION-MAKING PROCESS 75 6.3 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA 75 6.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 75 6.3.2 BUYING CRITERIA 76 6.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 77 6.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 78 6.5.1 UNMET NEEDS 78 6.5.2 END USER EXPECTATIONS 79 6.6 MARKET PROFITABILITY 79 7 REGULATORY LANDSCAPE 80 7.1 REGIONAL REGULATIONS AND COMPLIANCE 80 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS 81 7.1.2 REGULATORY FRAMEWORK 85 7.1.2.1 North America 85 7.1.2.2 Europe 86 7.1.2.3 Asia Pacific 87 7.1.2.4 Latin America 88 7.1.2.5 Middle East & Africa 88 7.1.3 INDUSTRY STANDARDS 89 8 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, AND AI ADOPTION 90 8.1 KEY EMERGING TECHNOLOGIES 90 8.1.1 WEARABLE SENSOR TECHNOLOGIES 90 8.1.2 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING ANALYTICS 90 8.1.3 MOBILE HEALTH (MHEALTH) PLATFORMS AND SMARTPHONE SENSORS 90 8.2 COMPLEMENTARY TECHNOLOGIES 91 8.2.1 INTERNET OF MEDICAL THINGS (IOMT) 91 8.2.2 TELEHEALTH AND REMOTE PATIENT MONITORING 91 8.3 ADJACENT TECHNOLOGIES 91 8.3.1 DIGITAL THERAPEUTICS 91 8.3.2 DIGITAL PATHOLOGY AND IMAGING AI 92 8.4 TECHNOLOGY/PRODUCT ROADMAP 92 8.5 PATENT ANALYSIS 93 8.5.1 PATENT PUBLICATION TRENDS IN DIGITAL BIOMARKERS MARKET 93 8.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 94   8.6 FUTURE APPLICATIONS 96 8.6.1 AI-ENABLED INTELLIGENT SCREENING AND INTERPRETATION 97 8.6.2 CONTINUOUS AND PREDICTIVE HEALTH MONITORING APPLICATIONS 97 8.6.3 DECENTRALIZED, REMOTE, AND REAL-WORLD DATA ECOSYSTEMS 97 8.7 IMPACT OF AI/GEN AI ON DIGITAL BIOMARKERS MARKET 97 8.7.1 INTRODUCTION 97 8.7.2 MARKET POTENTIAL OF AI/GEN AI IN DIGITAL BIOMARKERS MARKET 98 8.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 100 8.7.3.1 Early Alzheimer’s detection using mobile-based cognitive assessment platforms 100 8.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 100 8.7.4.1 Digital health market 101 8.7.4.2 Remote patient monitoring market 101 8.7.4.3 Telehealth & telemedicine market 101 8.7.5 USER READINESS AND IMPACT ASSESSMENT 101 8.7.5.1 User readiness 101 8.7.5.1.1 User A: Pharmaceutical & biotechnology companies 101 8.7.5.1.2 User B: Contract research organizations (CROs) 102 8.7.5.2 Impact assessment 102 8.7.5.2.1 User A: Pharmaceutical & biotechnology companies 102 8.7.5.2.1.1 Implementation 102 8.7.5.2.1.2 Impact 102 8.7.5.2.2 User B: Contract research organizations 102 8.7.5.2.2.1 Implementation 102 8.7.5.2.2.2 Impact 103 9 DIGITAL BIOMARKERS MARKET, BY TYPE 104 9.1 INTRODUCTION 105 9.2 PHYSIOLOGICAL BIOMARKERS 105 9.2.1 SEGMENT LEADS MARKET ADOPTION THROUGH CLINICAL VALIDATION AND AI-DRIVEN ANALYTICS 105 9.3 IDIOSYNCRATIC BIOMARKERS 107 9.3.1 PRECISION MEDICINE DRIVEN THROUGH PERSONALIZED, INDIVIDUAL-LEVEL DATA INSIGHTS 107 9.4 COGNITIVE BIOMARKERS 109 9.4.1 ENABLE SCALABLE AND OBJECTIVE MEASUREMENT OF NEUROLOGICAL FUNCTION THROUGH ADVANCED ANALYTICS 109 9.5 VOCAL BIOMARKERS 110 9.5.1 AI-POWERED VOICE ANALYSIS ENABLES SCALABLE MENTAL HEALTH MONITORING 110 9.6 OTHER BIOMARKERS 112   10 DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA 114 10.1 INTRODUCTION 115 10.2 CARDIOVASCULAR 115 10.2.1 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE/SECONDARY PREVENTION 117 10.2.1.1 Continuous risk monitoring and predictive insights in cardiovascular disease management – key driver 117 10.2.2 HEART FAILURE (HFREF & HFPEF) 118 10.2.2.1 Demand driven by advanced early detection and remote monitoring in heart failure management 118 10.2.3 HYPERTENSION 119 10.2.3.1 Transforming blood pressure assessment from episodic to continuous monitoring 119 10.2.4 ATRIAL FIBRILLATION/STROKE PREVENTION 120 10.2.4.1 Unlocking subclinical AF identification via long-duration rhythm analytics 120 10.2.5 PULMONARY HYPERTENSION 121 10.2.5.1 Advancement of functional endpoint measurement beyond traditional walk tests to boost growth 121 10.2.6 STRUCTURAL HEART DISEASE/INTERVENTIONAL CARDIOLOGY 121 10.2.6.1 Remote post-procedural surveillance in structural heart interventions to drive segment 121 10.3 ONCOLOGY 122 10.3.1 SOLID TUMORS 124 10.3.1.1 BREAST CANCER 125 10.3.1.1.1 Segment driven by enhanced tumor characterization through AI-driven imaging and pathology analytics 125 10.3.1.2 LUNG CANCER 126 10.3.1.2.1 Enhanced immunotherapy response prediction using imaging biomarkers to boost growth 126 10.3.1.3 Prostate cancer 127 10.3.1.3.1 Segment growth propelled by reduced variability in cancer grading with quantitative digital pathology 127 10.3.1.4 COLORECTAL CANCER 127 10.3.1.4.1 Enhanced gastrointestinal oncology trials with decentralized functional endpoints – major driver 127 10.3.1.5 BRAIN TUMOR 128 10.3.1.5.1 Enhanced tumor monitoring with advanced MRI and volumetric analytics 128 10.3.1.6 OTHER SOLID TUMORS 129 10.3.1.6.1 Extension of digital biomarker utility across rare and heterogeneous tumor types to drive segment 129 10.3.2 HEMATOLOGIC MALIGNANCIES 130 10.3.2.1 LEUKEMIA 131 10.3.2.1.1 Enhanced MRD detection and quantification through AI-driven analytics to boost market 131 10.3.2.2 LYMPHOMA 132 10.3.2.2.1 Capturing immune response dynamics with continuous digital monitoring – key benefit 132 10.3.2.3 MULTIPLE MYELOMA 133 10.3.2.3.1 Segment growth driven by enhanced disease burden assessment with integrated imaging and pathology analytics 133 10.3.2.4 OTHER HEMATOLOGIC MALIGNANCIES 134 10.3.2.4.1 High-sensitivity endpoint generation in small patient populations to boost market 134 10.4 DIABETES 135 10.4.1 CONTINUOUS MONITORING PLATFORMS EXPANDING INTO HOLISTIC CARDIOMETABOLIC RISK PREDICTION 135 10.5 MENTAL HEALTH & BEHAVIORAL HEALTH 137 10.5.1 PASSIVE BEHAVIORAL AND VOICE DATA ENABLE SCALABLE OBJECTIVE CONDITION MONITORING 137 10.6 RESPIRATORY DISORDERS 138 10.6.1 EARLY EXACERBATION DETECTION THROUGH CONTINUOUS MONITORING REDUCES HOSPITALIZATIONS AND COSTS 138 10.7 LIFESTYLE & WELLNESS IMPROVEMENT 140 10.7.1 EXPANDING PREVENTIVE HEALTH THROUGH CONTINUOUS BEHAVIORAL DATA INSIGHTS 140 10.8 NEUROLOGY 142 10.8.1 REGULATORY VALIDATION OF DIGITAL ENDPOINTS TO ACCELERATE EARLY DETECTION AND TRIAL ADOPTION 142 10.9 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT 144 10.9.1 EMPLOYER-BACKED DIGITAL CARE AND MOTION TRACKING TO DRIVE SCALABLE REHABILITATION SOLUTIONS 144 10.10 WOMEN'S HEALTH & REPRODUCTIVE HEALTH 146 10.10.1 ADDRESSING UNMET NEEDS THROUGH DATA-DRIVEN WOMEN’S HEALTH INSIGHTS 146 10.11 OTHER DISEASES 148 10.11.1 EXPANDING USE CASES TO DRIVE ADOPTION ACROSS CHRONIC AND UNDERSERVED CONDITIONS 148 11 DIGITAL BIOMARKERS MARKET, BY APPLICATION 149 11.1 INTRODUCTION 150 11.2 CLINICAL RESEARCH 150 11.2.1 PHASE II 152 11.2.1.1 Critical role in early-stage validation and risk reduction in clinical development 152 11.2.2 PHASE III 153 11.2.2.1 Regulatory-grade endpoint validation drives high-stakes clinical trial adoption 153   11.2.3 PHASE IV 154 11.2.3.1 Real-world evidence demand drives scalable continuous monitoring and reimbursement adoption 154 11.3 CLINICAL CARE 155 11.3.1 RISING CHRONIC DISEASE BURDEN DRIVING SHIFT TO CONTINUOUS PROACTIVE CARE 155 12 DIGITAL BIOMARKER MARKET, BY END USER 157 12.1 INTRODUCTION 158 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 158 12.2.1 CLINICAL TRIAL DRIVEN EFFICIENCY THROUGH HIGH-IMPACT DIGITAL ENDPOINTS 158 12.3 CONTRACT RESEARCH ORGANIZATIONS 159 12.3.1 END-TO-END DIGITAL TRIAL EXECUTION ENABLED THROUGH ADVANCED ANALYTICS 159 12.4 HOSPITALS & SPECIALTY CLINICS 160 12.4.1 ENHANCED CLINICAL OUTCOMES WITH REAL-TIME, DATA-DRIVEN CARE DELIVERY 160 12.5 OTHER END USERS 161 12.5.1 PUBLIC FUNDING AND REAL-WORLD DATA INITIATIVES ACCELERATE ECOSYSTEM-WIDE ADOPTION 161 13 DIGITAL BIOMARKERS MARKET, BY REGION 163 13.1 INTRODUCTION 164 13.2 NORTH AMERICA 164 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 165 13.2.2 US 170 13.2.2.1 Regulatory advancements and pharma-tech convergence drive market growth 170 13.2.3 CANADA 174 13.2.3.1 Increasing integration of AI-driven screening and remote monitoring to drive market 174 13.3 EUROPE 178 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 179 13.3.2 GERMANY 183 13.3.2.1 Strong clinical trial ecosystem and progressive digital health regulation to drive market 183 13.3.3 FRANCE 187 13.3.3.1 Strong clinical trial base and evidence-driven regulatory pathways to drive market 187 13.3.4 UK 191 13.3.4.1 Strong NHS data infrastructure and push for data-enabled clinical trials to drive market 191 13.3.5 ITALY 195 13.3.5.1 Strong clinical research activity and oncology-driven demand to shape market growth 195 13.3.6 SPAIN 199 13.3.6.1 Strong clinical trial leadership and high domestic research concentration to drive market 199 13.3.7 REST OF EUROPE 203 13.4 LATIN AMERICA 208 13.4.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 208 13.4.2 BRAZIL 212 13.4.2.1 Expanding digital health ecosystem and regulatory reforms to drive digital biomarkers adoption 212 13.4.3 MEXICO 216 13.4.3.1 Growing clinical trial participation and digital transformation to drive digital biomarkers adoption 216 13.4.4 REST OF LATIN AMERICA 220 13.5 ASIA PACIFIC 224 13.5.1 ASIA PACIFIC: CLINICAL TRIAL INITIATIONS IN 2014 AND 2024 225 13.5.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 225 13.5.3 CHINA 230 13.5.3.1 Expanding clinical trial leadership and advancing digital health ecosystem to drive market 230 13.5.4 JAPAN 234 13.5.4.1 Declining clinical trial activity despite strong legacy position to impact market 234 13.5.5 INDIA 238 13.5.5.1 Rapid clinical trial growth, cost advantages, and regulatory reforms to drive market 238 13.5.6 AUSTRALIA 242 13.5.6.1 Strong early-phase trial capabilities and advanced research infrastructure to drive market 242 13.5.7 SOUTH KOREA 246 13.5.7.1 Steady clinical trial growth and strong innovation ecosystem to drive market 246 13.5.8 REST OF ASIA PACIFIC 250 13.6 MIDDLE EAST & AFRICA 255 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 255 13.6.2 GCC COUNTRIES 260 13.6.2.1 Strong digital health transformation and growing clinical research activity to drive adoption 260 13.6.3 SAUDI ARABIA 264 13.6.3.1 Expanding clinical research activity and government-led initiatives to drive market 264 13.6.4 UAE 268 13.6.4.1 Advancing digital health innovation and strategic collaborations – key growth drivers 268 13.6.5 OTHER GCC COUNTRIES 272 13.6.5.1 Regulatory initiatives, national health visions, and digital health infrastructure boost market growth 272 13.6.6 SOUTH AFRICA 276 13.6.6.1 Leading clinical research hub in Africa with strong infrastructure 276 13.6.7 REST OF MIDDLE EAST & AFRICA 280 14 COMPETITIVE LANDSCAPE 285 14.1 OVERVIEW 285 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 285 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL BIOMARKERS MARKET 286 14.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 288 14.4 MARKET SHARE ANALYSIS, 2025 289 14.5 BRAND COMPARISON 292 14.6 COMPANY VALUATION & FINANCIAL METRICS 293 14.6.1 FINANCIAL METRICS 293 14.6.2 COMPANY VALUATION 293 14.7 COMPANY EVALUATION MATRIX 294 14.7.1 STARS 294 14.7.2 EMERGING LEADERS 294 14.7.3 PERVASIVE PLAYERS 294 14.7.4 PARTICIPANTS 294 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 296 14.7.5.1 Company footprint 296 14.7.5.2 Region footprint 297 14.7.5.3 Type footprint 298 14.7.5.4 Therapeutic area footprint 299 14.7.5.5 Application footprint 300 14.7.5.6 End user footprint 301 14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 302 14.8.1 PROGRESSIVE COMPANIES 302 14.8.2 RESPONSIVE COMPANIES 302 14.8.3 DYNAMIC COMPANIES 302 14.8.4 STARTING BLOCKS 302 14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 304 14.8.5.1 Detailed list of key startups/SMEs 304 14.8.5.2 Competitive benchmarking of startups/SMEs 305 14.9 COMPETITIVE SCENARIO 306 14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 306 14.9.2 DEALS 307 14.9.3 OTHER DEVELOPMENTS 308   15 COMPANY PROFILES 309 15.1 KEY PLAYERS 309 15.1.1 IXICO PLC 309 15.1.1.1 Business overview 309 15.1.1.2 Products offered 310 15.1.1.3 Recent developments 311 15.1.1.3.1 Product launches/approvals 311 15.1.1.3.2 Deals 311 15.1.1.4 MnM view 312 15.1.1.4.1 Key strengths 312 15.1.1.4.2 Strategic choices 313 15.1.1.4.3 Weaknesses and competitive threats 313 15.1.2 AMETRIS, LLC 314 15.1.2.1 Business overview 314 15.1.2.2 Products Offered 315 15.1.2.3 Recent developments 315 15.1.2.3.1 Product launches/enhancements 315 15.1.2.3.2 Deals 316 15.1.2.4 MnM view 318 15.1.2.4.1 Key strengths 318 15.1.2.4.2 Strategic choices 318 15.1.2.4.3 Weaknesses and competitive threats 318 15.1.3 EMPATICA INC. 319 15.1.3.1 Business overview 319 15.1.3.2 Products/Solutions offered 320 15.1.3.3 Recent developments 321 15.1.3.3.1 Product launches/approvals 321 15.1.3.3.2 Deals 322 15.1.3.4 MnM view 323 15.1.3.4.1 Key strengths 323 15.1.3.4.2 Strategic choices 323 15.1.3.4.3 Weaknesses and competitive threats 323 15.1.4 ALIVECOR, INC. 324 15.1.4.1 Business overview 324 15.1.4.2 Products offered 325 15.1.4.3 Recent developments 326 15.1.4.3.1 Product launches/approvals 326 15.1.4.3.2 Deals 326 15.1.4.4 MnM view 328 15.1.4.4.1 Key strengths 328 15.1.4.4.2 Strategic choices 328 15.1.4.4.3 Weaknesses and competitive threats 328 15.1.5 CONNEQT HEALTH 329 15.1.5.1 Business overview 329 15.1.5.2 Products offered 331 15.1.5.3 Recent developments 331 15.1.5.3.1 Product enhancements/approvals 331 15.1.5.4 MnM view 332 15.1.5.4.1 Key strengths 332 15.1.5.4.2 Strategic choices 332 15.1.5.4.3 Weaknesses and competitive threats 332 15.1.6 VIVOSENSE 333 15.1.6.1 Business overview 333 15.1.6.2 Products offered 333 15.1.6.2.1 Other developments 334 15.1.7 BIOSENSICS 335 15.1.7.1 Business overview 335 15.1.7.2 Products offered 336 15.1.7.3 Recent developments 336 15.1.7.3.1 Product launches/approvals 336 15.1.7.3.2 Deals 337 15.1.8 LUNIT INC. 338 15.1.8.1 Business overview 338 15.1.8.2 Products offered 340 15.1.8.3 Recent developments 341 15.1.8.3.1 Product launches/approvals 341 15.1.8.3.2 Deals 342 15.1.9 AKILI, INC. 345 15.1.9.1 Business overview 345 15.1.9.2 Products offered 345 15.1.9.3 Recent developments 346 15.1.9.3.1 Deals 346 15.1.10 QUIBIM 347 15.1.10.1 Business overview 347 15.1.10.2 Products offered 347 15.1.10.3 Recent developments 349 15.1.10.3.1 Product launches/approvals/enhancements 349 15.1.10.3.2 Deals 350 15.1.11 CLARIO 351 15.1.11.1 Business overview 351 15.1.11.2 Products offered 352 15.1.11.3 Recent developments 353 15.1.11.3.1 Deals 353   15.1.12 PROSCIA INC. 356 15.1.12.1 Business overview 356 15.1.12.2 Products offered 357 15.1.12.3 Recent developments 358 15.1.12.3.1 Product launches/approvals 358 15.1.12.3.2 Deals 358 15.1.13 KONEKSA HEALTH 361 15.1.13.1 Business overview 361 15.1.13.2 Products offered 362 15.1.13.3 Recent developments 363 15.1.13.3.1 Product launches 363 15.1.13.3.2 Deals 364 15.1.14 LINUS HEALTH 365 15.1.14.1 Business overview 365 15.1.14.2 Products offered 366 15.1.14.3 Recent developments 366 15.1.14.3.1 Product launches/approvals 366 15.1.14.3.2 Deals 367 15.2 OTHER PLAYERS 369 15.2.1 SONDE HEALTH, INC. 369 15.2.2 ALTOIDA 370 15.2.3 IMVARIA INC. 371 15.2.4 CUMULUS NEUROSCIENCE LIMITED 372 15.2.5 DELVE HEALTH 373 15.2.6 FEEL THERAPEUTICS 374 15.2.7 NANOWEAR INC. 375 15.2.8 EXOSYSTEMS 376 15.2.9 CARDIOSIGNAL 377 15.2.10 IMAGENE AI LTD. 378 15.2.11 NEUROTRACK TECHNOLOGIES, INC. 379 16 RESEARCH METHODOLOGY 380 16.1 RESEARCH APPROACH 380 16.1.1 SECONDARY RESEARCH 381 16.1.1.1 Key data from secondary sources 382 16.1.2 PRIMARY RESEARCH 382 16.1.2.1 Primary sources 383 16.1.2.2 Key data from primary sources 384 16.1.2.3 Breakdown of primaries 384 16.1.2.4 Insights from primary experts 385   16.2 RESEARCH METHODOLOGY DESIGN 385 16.3 MARKET SIZE ESTIMATION 386 16.4 MARKET BREAKDOWN DATA TRIANGULATION 391 16.5 MARKET SHARE ESTIMATION 392 16.6 STUDY ASSUMPTIONS 392 16.7 RESEARCH LIMITATIONS 393 16.7.1 METHODOLOGY-RELATED LIMITATIONS 393 16.8 RISK ASSESSMENT 393 17 APPENDIX 394 17.1 DISCUSSION GUIDE 394 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 398 17.3 CUSTOMIZATION OPTIONS 400 17.4 RELATED REPORTS 400 17.5 AUTHOR DETAILS 401
圖表清單 List of Tables & Figures
TABLE 1 USD EXCHANGE RATES 39 TABLE 2 DIGITAL BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 59 TABLE 3 DIGITAL BIOMARKERS MARKET: ROLE IN ECOSYSTEM 63 TABLE 4 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY KEY PLAYER (2025) 64 TABLE 5 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY REGION (2025) 65 TABLE 6 CASE 1: EMPATICA – INTEGRATION OF DIGITAL BIOMARKERS INTO HIGH-ALTITUDE ENDOCRINOLOGY RESEARCH (APEX 7 HICORT STUDY) 68 TABLE 7 CASE 2: VIVOSENSE – DIGITAL BIOMARKERS FOR PTSD MONITORING AND ASSESSMENT 69 TABLE 8 CASE 3: DELVE HEALTH – IMPROVED DATA INTEGRITY IN CLINICAL TRIALS WITH DIGITAL BIOMARKERS 70 TABLE 9 US ADJUSTED RECIPROCAL TARIFF RATES 71 TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%) 76 TABLE 11 KEY BUYING CRITERIA FOR TOP THREE END USERS 77 TABLE 12 UNMET NEEDS IN DIGITAL BIOMARKERS MARKET 78 TABLE 13 END USER EXPECTATIONS IN DIGITAL BIOMARKERS MARKET 79 TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 19 REGULATORY SCENARIO IN NORTH AMERICA 85 TABLE 20 REGULATORY SCENARIO IN EUROPE 86 TABLE 21 REGULATORY SCENARIO IN ASIA PACIFIC 87 TABLE 22 REGULATORY SCENARIO IN LATIN AMERICA 88 TABLE 23 REGULATORY SCENARIO IN MIDDLE EAST & AFRICA 88 TABLE 24 DIGITAL BIOMARKERS MARKET: JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES 94 TABLE 25 DIGITAL BIOMARKERS MARKET: LIST OF PATENTS/PATENT APPLICATIONS 96 TABLE 26 DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 105 TABLE 27 PHYSIOLOGICAL BIOMARKERS: MAJOR PLAYERS AND OFFERINGS 106 TABLE 28 PHYSIOLOGICAL BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 107 TABLE 29 IDIOSYNCRATIC BIOMARKERS: MAJOR PLAYERS AND OFFERINGS 108 TABLE 30 IDIOSYNCRATIC BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 108 TABLE 31 COGNITIVE BIOMARKERS: MAJOR PLAYERS AND OFFERINGS 109 TABLE 32 COGNITIVE BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 110 TABLE 33 VOCAL BIOMARKERS: MAJOR PLAYERS AND OFFERINGS 111 TABLE 34 VOCAL BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 111 TABLE 35 OTHER BIOMARKERS: MAJOR PLAYERS AND OFFERINGS 112 TABLE 36 OTHER BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 113 TABLE 37 DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 115 TABLE 38 CARDIOVASCULAR: MAJOR PLAYERS AND OFFERINGS 116 TABLE 39 CARDIOVASCULAR: DIGITAL BIOMARKERS MARKET, BY CONDITION, 2024–2031 (USD MILLION) 117 TABLE 40 CARDIOVASCULAR: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 117 TABLE 41 ASCVD/SECONDARY PREVENTION: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 42 HEART FAILURE (HFREF & HFPEF): DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 43 HYPERTENSION: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 44 ATRIAL FIBRILLATION/STROKE PREVENTION: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 45 PULMONARY HYPERTENSION: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 121 TABLE 46 STRUCTURAL HEART DISEASE/INTERVENTIONAL CARDIOLOGY: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 47 ONCOLOGY: MAJOR PLAYERS AND OFFERINGS 123 TABLE 48 ONCOLOGY: DIGITAL BIOMARKERS MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION) 124 TABLE 49 ONCOLOGY: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 50 SOLID TUMORS: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 125 TABLE 51 SOLID TUMORS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 52 BREAST CANCER: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 53 LUNG CANCER: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 54 PROSTATE CANCER: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 55 COLORECTAL CANCER: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 128 TABLE 56 BRAIN TUMOR: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 57 OTHER SOLID TUMORS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 58 HEMATOLOGIC MALIGNANCIES: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 130 TABLE 59 HEMATOLOGIC MALIGNANCIES: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 60 LEUKEMIA: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 61 LYMPHOMA: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 62 MULTIPLE MYELOMA: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 134 TABLE 63 OTHER HEMATOLOGIC MALIGNANCIES: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 64 DIABETES: MAJOR PLAYERS AND OFFERINGS 136 TABLE 65 DIABETES: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 66 MENTAL HEALTH & BEHAVIORAL HEALTH: MAJOR PLAYERS AND OFFERINGS 138 TABLE 67 MENTAL HEALTH & BEHAVIORAL HEALTH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 68 RESPIRATORY DISORDERS: MAJOR PLAYERS AND OFFERINGS 139 TABLE 69 RESPIRATORY DISORDERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 70 LIFESTYLE & WELLNESS IMPROVEMENT: MAJOR PLAYERS AND OFFERINGS 141 TABLE 71 LIFESTYLE & WELLNESS IMPROVEMENT: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 72 NEUROLOGY: MAJOR PLAYERS AND OFFERINGS 143 TABLE 73 NEUROLOGY: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 74 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT: MAJOR PLAYERS AND OFFERINGS 145 TABLE 75 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 76 WOMEN'S HEALTH & REPRODUCTIVE HEALTH: MAJOR PLAYERS AND OFFERINGS 147 TABLE 77 WOMEN'S HEALTH & REPRODUCTIVE HEALTH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 78 OTHER DISEASES: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 79 DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 150 TABLE 80 CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY PHASE, 2024–2031 (USD MILLION) 151 TABLE 81 CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 82 PHASE II CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 83 PHASE III CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 154 TABLE 84 PHASE IV CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 85 CLINICAL CARE: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 86 DIGITAL BIOMARKER MARKET, BY END USER, 2024–2031 (USD MILLION) 158 TABLE 87 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 88 CONTRACT RESEARCH ORGANIZATIONS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 160 TABLE 89 HOSPITALS & SPECIALTY CLINICS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 161 TABLE 90 OTHER END USERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 162 TABLE 91 DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 92 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 93 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 94 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 167 TABLE 95 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 167 TABLE 96 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 168 TABLE 97 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 168 TABLE 98 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 168 TABLE 99 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 169 TABLE 100 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 169 TABLE 101 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 169 TABLE 102 US: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 171 TABLE 103 US: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 171 TABLE 104 US: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 172 TABLE 105 US: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 172 TABLE 106 US: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 107 US: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 108 US: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 173 TABLE 109 US: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 174 TABLE 110 US: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 174 TABLE 111 CANADA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 175 TABLE 112 CANADA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 175 TABLE 113 CANADA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 176 TABLE 114 CANADA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 176 TABLE 115 CANADA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 116 CANADA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 117 CANADA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 177 TABLE 118 CANADA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 178 TABLE 119 CANADA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 178 TABLE 120 EUROPE: DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 121 EUROPE: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 180 TABLE 122 EUROPE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 180 TABLE 123 EUROPE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 181 TABLE 124 EUROPE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 181 TABLE 125 EUROPE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 126 EUROPE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 127 EUROPE: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 182 TABLE 128 EUROPE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 183 TABLE 129 EUROPE: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 183 TABLE 130 GERMANY: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 184 TABLE 131 GERMANY: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 184 TABLE 132 GERMANY: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 185 TABLE 133 GERMANY: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 185 TABLE 134 GERMANY: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 135 GERMANY: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 136 GERMANY: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 186 TABLE 137 GERMANY: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 187 TABLE 138 GERMANY: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 187 TABLE 139 FRANCE: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 188 TABLE 140 FRANCE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 188 TABLE 141 FRANCE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 189 TABLE 142 FRANCE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 189 TABLE 143 FRANCE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 144 FRANCE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 145 FRANCE: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 190 TABLE 146 FRANCE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 191 TABLE 147 FRANCE: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 191 TABLE 148 UK: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 149 UK: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 192 TABLE 150 UK: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 193 TABLE 151 UK: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 193 TABLE 152 UK: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 153 UK: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 154 UK: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 194 TABLE 155 UK: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 195 TABLE 156 UK: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 195 TABLE 157 ITALY: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 196 TABLE 158 ITALY: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 196 TABLE 159 ITALY: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 197 TABLE 160 ITALY: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 197 TABLE 161 ITALY: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 162 ITALY: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 163 ITALY: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 198 TABLE 164 ITALY: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 199 TABLE 165 ITALY: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 199 TABLE 166 SPAIN: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 167 SPAIN: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 200 TABLE 168 SPAIN: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 201 TABLE 169 SPAIN: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 201 TABLE 170 SPAIN: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 171 SPAIN: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 172 SPAIN: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 202 TABLE 173 SPAIN: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 203 TABLE 174 SPAIN: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 203 TABLE 175 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 176 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 205 TABLE 177 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 205 TABLE 178 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 206 TABLE 179 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 180 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 181 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 207 TABLE 182 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 207 TABLE 183 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 207 TABLE 184 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 185 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 186 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 209 TABLE 187 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 210 TABLE 188 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 210 TABLE 189 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 190 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 191 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 211 TABLE 192 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 212 TABLE 193 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 212 TABLE 194 BRAZIL: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 195 BRAZIL: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 213 TABLE 196 BRAZIL: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 214 TABLE 197 BRAZIL: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 214 TABLE 198 BRAZIL: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 199 BRAZIL: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 200 BRAZIL: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 215 TABLE 201 BRAZIL: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 216 TABLE 202 BRAZIL: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 216 TABLE 203 MEXICO: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 204 MEXICO: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 217 TABLE 205 MEXICO: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 218 TABLE 206 MEXICO: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 218 TABLE 207 MEXICO: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 208 MEXICO: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 209 MEXICO: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 219 TABLE 210 MEXICO: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 220 TABLE 211 MEXICO: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 220 TABLE 212 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 213 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 221 TABLE 214 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 222 TABLE 215 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 222 TABLE 216 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 217 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 218 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 223 TABLE 219 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 224 TABLE 220 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 224 TABLE 221 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 222 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 223 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 227 TABLE 224 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 228 TABLE 225 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 228 TABLE 226 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 227 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 228 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 229 TABLE 229 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 230 TABLE 230 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 230 TABLE 231 CHINA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 232 CHINA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 231 TABLE 233 CHINA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 232 TABLE 234 CHINA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 232 TABLE 235 CHINA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 236 CHINA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 237 CHINA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 233 TABLE 238 CHINA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 239 CHINA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 234 TABLE 240 JAPAN: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 241 JAPAN: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 235 TABLE 242 JAPAN: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 236 TABLE 243 JAPAN: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 236 TABLE 244 JAPAN: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 245 JAPAN: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 246 JAPAN: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 237 TABLE 247 JAPAN: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 238 TABLE 248 JAPAN: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 238 TABLE 249 INDIA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 250 INDIA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 239 TABLE 251 INDIA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 240 TABLE 252 INDIA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 240 TABLE 253 INDIA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 254 INDIA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 255 INDIA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 241 TABLE 256 INDIA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 242 TABLE 257 INDIA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 242 TABLE 258 AUSTRALIA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 259 AUSTRALIA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 243 TABLE 260 AUSTRALIA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 244 TABLE 261 AUSTRALIA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 244 TABLE 262 AUSTRALIA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 263 AUSTRALIA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 264 AUSTRALIA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 245 TABLE 265 AUSTRALIA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 266 AUSTRALIA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 267 SOUTH KOREA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 268 SOUTH KOREA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 247 TABLE 269 SOUTH KOREA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 248 TABLE 270 SOUTH KOREA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 248 TABLE 271 SOUTH KOREA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 272 SOUTH KOREA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 273 SOUTH KOREA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 249 TABLE 274 SOUTH KOREA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 250 TABLE 275 SOUTH KOREA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 250 TABLE 276 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 277 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 252 TABLE 278 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 252 TABLE 279 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 253 TABLE 280 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 281 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 282 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 254 TABLE 283 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 254 TABLE 284 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 254 TABLE 285 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 286 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 287 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 257 TABLE 288 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 257 TABLE 289 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 258 TABLE 290 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 291 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 292 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 259 TABLE 293 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 259 TABLE 294 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 295 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 296 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 297 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 261 TABLE 298 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 262 TABLE 299 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 262 TABLE 300 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 301 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 302 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263 TABLE 303 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 264 TABLE 304 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 264 TABLE 305 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 306 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 265 TABLE 307 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 266 TABLE 308 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 266 TABLE 309 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 310 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 311 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 267 TABLE 312 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 268 TABLE 313 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 268 TABLE 314 UAE: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 315 UAE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 269 TABLE 316 UAE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 270 TABLE 317 UAE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 270 TABLE 318 UAE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 319 UAE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 320 UAE: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 271 TABLE 321 UAE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 272 TABLE 322 UAE: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 272 TABLE 323 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 324 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 273 TABLE 325 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 274 TABLE 326 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 274 TABLE 327 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 328 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 329 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 275 TABLE 330 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 276 TABLE 331 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 276 TABLE 332 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 333 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 277 TABLE 334 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 278 TABLE 335 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 278 TABLE 336 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 337 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 338 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 279 TABLE 339 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 280 TABLE 340 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 280 TABLE 341 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 342 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 281 TABLE 343 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 282 TABLE 344 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 282 TABLE 345 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 346 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 347 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 283 TABLE 348 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 283 TABLE 349 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 284 TABLE 350 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL BIOMARKERS MARKET, JANUARY 2022–MARCH 2026 286 TABLE 351 DIGITAL BIOMARKERS MARKET: DEGREE OF COMPETITION 290 TABLE 352 DIGITAL BIOMARKERS MARKET: REGION FOOTPRINT (14 COMPANIES) 297 TABLE 353 DIGITAL BIOMARKERS MARKET: TYPE FOOTPRINT (14 COMPANIES) 298 TABLE 354 DIGITAL BIOMARKERS MARKET: THERAPEUTIC AREA FOOTPRINT (14 COMPANIES) 299 TABLE 355 DIGITAL BIOMARKERS MARKET: APPLICATION FOOTPRINT (14 COMPANIES) 300 TABLE 356 DIGITAL BIOMARKERS MARKET: END USER FOOTPRINT (14 COMPANIES) 301 TABLE 357 DIGITAL BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 304 TABLE 358 DIGITAL BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY REGION 305 TABLE 359 DIGITAL BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY TYPE 305 TABLE 360 DIGITAL BIOMARKERS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2022–MARCH 2026 306 TABLE 361 DIGITAL BIOMARKERS MARKET: DEALS, JANUARY 2022–MARCH 2026 307 TABLE 362 DIGITAL BIOMARKERS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2026 308 TABLE 363 IXICO PLC: COMPANY OVERVIEW 309 TABLE 364 IXICO PLC: PRODUCTS OFFERED 310 TABLE 365 IXICO PLC.: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 311 TABLE 366 IXICO PLC.: DEALS, JANUARY 2022–MARCH 2026 311 TABLE 367 AMETRIS, LLC: COMPANY OVERVIEW 314 TABLE 368 AMETRIS LLC: PRODUCTS OFFERED 315 TABLE 369 AMETRIS LLC: PRODUCT LAUNCHES/ENHANCEMENTS, JANUARY 2022–MARCH 2026 315 TABLE 370 AMETRIS, LLC: DEALS, JANUARY 2022–MARCH 2026 316 TABLE 371 EMPATICA INC.: COMPANY OVERVIEW 319 TABLE 372 EMPATICA INC.: PRODUCTS/SOLUTIONS OFFERED 320 TABLE 373 EMPATICA INC.: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 321 TABLE 374 EMPATICA INC.: DEALS, JANUARY 2022–MARCH 2026 322 TABLE 375 ALIVECOR, INC.: COMPANY OVERVIEW 324 TABLE 376 ALIVECOR, INC.: PRODUCTS OFFERED 325 TABLE 377 ALIVECOR, INC.: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 326 TABLE 378 ALIVECOR, INC.: DEALS, JANUARY 2022–MARCH 2026 326 TABLE 379 CONNEQT HEALTH: COMPANY OVERVIEW 329 TABLE 380 CONNEQT HEALTH: PRODUCTS OFFERED 331 TABLE 381 CONNEQT HEALTH: PRODUCT ENHANCEMENTS/APPROVALS, JANUARY 2022–MARCH 2026 331 TABLE 382 VIVOSENSE: COMPANY OVERVIEW 333 TABLE 383 VIVOSENSE: PRODUCTS OFFERED 333 TABLE 384 VIVOSENSE: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2026 334 TABLE 385 BIOSENSICS: COMPANY OVERVIEW 335 TABLE 386 BIOSENSICS: PRODUCTS OFFERED 336 TABLE 387 BIOSENSICS: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 336 TABLE 388 BIOSENSICS: DEALS, JANUARY 2022–MARCH 2026 337 TABLE 389 LUNIT INC.: COMPANY OVERVIEW 338 TABLE 390 LUNIT INC.: PRODUCTS OFFERED 340 TABLE 391 LUNIT INC.: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 341 TABLE 392 LUNIT INC.: DEALS, JANUARY 2022–MARCH 2026 342 TABLE 393 AKILI, INC.: COMPANY OVERVIEW 345 TABLE 394 AKILI, INC.: PRODUCTS OFFERED 345 TABLE 395 AKILI, INC.: DEALS, JANUARY 2022–MARCH 2026 346 TABLE 396 QUIBIM: COMPANY OVERVIEW 347 TABLE 397 QUIBIM: PRODUCTS OFFERED 347 TABLE 398 QUIBIM: PRODUCT LAUNCHES/APPROVALS/ENHANCEMENTS, JANUARY 2022–MARCH 2026 349 TABLE 399 QUIBIM: DEALS, JANUARY 2022–MARCH 2026 350 TABLE 400 CLARIO: COMPANY OVERVIEW 351 TABLE 401 CLARIO: PRODUCTS OFFERED 352 TABLE 402 CLARIO: DEALS, JANUARY 2022–MARCH 2026 353 TABLE 403 PROSCIA INC.: COMPANY OVERVIEW 356 TABLE 404 PROSCIA INC.: PRODUCTS OFFERED 357 TABLE 405 PROSCIA INC.: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 358 TABLE 406 PROSCIA INC.: DEALS, JANUARY 2022–MARCH 2026 358 TABLE 407 KONEKSA HEALTH: COMPANY OVERVIEW 361 TABLE 408 KONEKSA HEALTH: PRODUCTS OFFERED 362 TABLE 409 KONEKSA HEALTH: PRODUCT LAUNCHES, JANUARY 2022–MARCH 2026 363 TABLE 410 KONEKSA HEALTH: DEALS, JANUARY 2022– MARCH 2026 364 TABLE 411 LINUS HEALTH: COMPANY OVERVIEW 365 TABLE 412 LINUS HEALTH: PRODUCTS OFFERED 366 TABLE 413 LINUS HEALTH: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 366 TABLE 414 LINUS HEALTH: DEALS, JANUARY 2022–MARCH 2026 367 TABLE 415 SONDE HEALTH, INC.: COMPANY OVERVIEW 369 TABLE 416 ALTOIDA: COMPANY OVERVIEW 370 TABLE 417 IMVARIA INC.: COMPANY OVERVIEW 371 TABLE 418 CUMULUS NEUROSCIENCE LIMITED: COMPANY OVERVIEW 372 TABLE 419 DELVE HEALTH: COMPANY OVERVIEW 373 TABLE 420 FEEL THERAPEUTICS: COMPANY OVERVIEW 374 TABLE 421 NANOWEAR INC.: COMPANY OVERVIEW 375 TABLE 422 EXOSYSTEMS: COMPANY OVERVIEW 376 TABLE 423 CARDIOSIGNAL: COMPANY OVERVIEW 377 TABLE 424 IMAGENE AI LTD.: COMPANY OVERVIEW 378 TABLE 425 NEUROTRACK TECHNOLOGIES, INC.: COMPANY OVERVIEW 379 TABLE 426 RISK ASSESSMENT: DIGITAL BIOMARKERS MARKET 393 FIGURE 1 DIGITAL BIOMARKERS MARKET SEGMENTATION 36 FIGURE 2 MARKET SCENARIO 42 FIGURE 3 GLOBAL DIGITAL BIOMARKERS MARKET, 2024–2031 42 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL BIOMARKERS MARKET, 2023–2026 43 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF DIGITAL BIOMARKERS MARKET 44 FIGURE 6 HIGH-GROWTH SEGMENTS IN DIGITAL BIOMARKERS MARKET, 2026–2031 45 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DIGITAL BIOMARKERS MARKET DURING FORECAST PERIOD 46 FIGURE 8 RISING IN CLINICAL TRIAL VOLUMES TO DRIVE GROWTH IN DIGITAL BIOMARKERS MARKET 47 FIGURE 9 CLINICAL RESEARCH APPLICATIONS ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025 48 FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 48 FIGURE 11 DIGITAL BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 58 FIGURE 12 DIGITAL BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 62 FIGURE 13 DIGITAL BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 63 FIGURE 14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67 FIGURE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 76 FIGURE 17 KEY BUYING CRITERIA FOR TOP THREE END USERS 77 FIGURE 18 DIGITAL BIOMARKERS MARKET: PATENT PUBLICATION TRENDS, 2015–2026 93 FIGURE 19 DIGITAL BIOMARKERS MARKET: JURISDICTION AND TOP APPLICANT ANALYSIS 94 FIGURE 20 DIGITAL BIOMARKERS MARKET: TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS), JANUARY 2015–APRIL 2026 95 FIGURE 21 MARKET POTENTIAL OF AI/GEN AI ON DIGITAL BIOMARKERS ACROSS INDUSTRIES 98 FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 100 FIGURE 23 TRIAL PHASES WITH DIGITAL ENDPOINTS 151 FIGURE 24 NORTH AMERICA: DIGITAL BIOMARKERS MARKET SNAPSHOT 165 FIGURE 25 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET SNAPSHOT 226 FIGURE 26 DIGITAL BIOMARKERS MARKET: REVENUE ANALYSIS OF KEY PLAYERS 288 FIGURE 27 DIGITAL BIOMARKERS MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 289 FIGURE 28 DIGITAL BIOMARKERS MARKET: BRAND COMPARATIVE ANALYSIS 292 FIGURE 29 EV/EBITDA OF KEY VENDORS 293 FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 293 FIGURE 31 DIGITAL BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (2025) 295 FIGURE 32 DIGITAL BIOMARKERS MARKET: COMPANY FOOTPRINT 296 FIGURE 33 DIGITAL BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 303 FIGURE 34 IXICO PLC: COMPANY SNAPSHOT (2025) 310 FIGURE 35 CONNEQT HEALTH: COMPANY SNAPSHOT (2025) 330 FIGURE 36 LUNIT INC.: COMPANY SNAPSHOT (2025) 339 FIGURE 37 RESEARCH DESIGN 380 FIGURE 38 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 384 FIGURE 39 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 386 FIGURE 40 BOTTOM-UP APPROACH 387 FIGURE 41 TOP-DOWN APPROACH 388 FIGURE 42 CAGR PROJECTIONS BASED ON DROC ANALYSIS OF DIGITAL BIOMARKERS INDUSTRY 389 FIGURE 43 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 389 FIGURE 44 DATA TRIANGULATION METHODOLOGY 391

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們